Glepaglutide
Phase 3Recruiting 0 watching 0 views this week📈 Rising
74
Development Stage
✓
Pre-clinical✓
Phase 1✓
Phase 24
Phase 35
ApprovedIndication / Disease
Short Bowel Syndrome
Conditions
Short Bowel Syndrome
Trial Timeline
Feb 11, 2026 → Feb 28, 2032
NCT ID
NCT07197944About Glepaglutide
Glepaglutide is a phase 3 stage product being developed by Zealand Pharma for Short Bowel Syndrome. The current trial status is recruiting. This product is registered under clinical trial identifier NCT07197944. Target conditions include Short Bowel Syndrome.
Hype Score Breakdown
Clinical
27
Activity
18
Company
7
Novelty
9
Community
10
Clinical Trials (7)
| NCT ID | Phase | Status |
|---|---|---|
| NCT07197944 | Phase 3 | Recruiting |
| NCT04991311 | Phase 3 | Completed |
| NCT04881825 | Phase 3 | Active |
| NCT04318743 | Phase 1 | Completed |
| NCT04178447 | Phase 1 | Completed |
| NCT03905707 | Phase 3 | Active |
| NCT03279302 | Phase 1 | Completed |
Competing Products
20 competing products in Short Bowel Syndrome
| Product | Company | Stage | Hype Score |
|---|---|---|---|
| somatropin + leuprorelin | Eli Lilly | Phase 3 | 77 |
| Growth Hormone | Eli Lilly | Approved | 85 |
| Pancreatic Enzyme | AbbVie | Phase 2 | 52 |
| Aromatase Inhibitor + Growth Hormone + Aromatase Inhibitor and Growth Hormone | AstraZeneca | Phase 3 | 77 |
| Oral, live, pentavalent rotavirus vaccine; RotaTeq(R) | Merck | Phase 1 | 33 |
| Saizen® + Saizen® | Merck | Phase 3 | 77 |
| r-metHuLeptin | Amgen | Phase 1 | 32 |
| Somapacitan + Norditropin® | Novo Nordisk | Phase 2 | 51 |
| Somatotropin growth hormone recombinant human | Pfizer | Approved | 84 |
| Genotropin (somatropin) | Pfizer | Approved | 84 |
| Genotropin + Genotropin | Pfizer | Phase 3 | 76 |
| GH treatment (Genotropin) + 1 year treatment with placebo followed by optional 3 years of GH treatment | Pfizer | Approved | 84 |
| Genotropin | Pfizer | Phase 2/3 | 64 |
| glepaglutide | Zealand Pharma | Phase 3 | 74 |
| Glepaglutide | Zealand Pharma | Phase 3 | 74 |
| ZP1848 | Zealand Pharma | Phase 2 | 49 |
| glepaglutide + Placebo | Zealand Pharma | Phase 3 | 74 |
| Glepaglutide | Zealand Pharma | Phase 3 | 74 |
| Glepaglutide 10 mg | Zealand Pharma | Phase 3 | 74 |
| Nutropin [Somatropin (rDNA origin) for injection] | Ipsen | Approved | 82 |